Redo AF Sub Study (of the Pure EP 2.0 Main Study)

Status Completed

Clinical Trial Summary

This study is a sub study of the Pure EP 2.0 trial. In a redo atrial fibrillation population, this study is designed to collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. These signals are later evaluated for clinical relevance and impact on the procedure.

Clinical Trial Description

Cardiac electrophysiologists rely on the display of electrograms when performing EP studies and catheter ablations in patients with arrhythmias. To achieve effective outcomes without complications, it is vital that the recording system enables the recognition of clearly abnormal (scared myocardium) and normal electrical signals. In a redo Atrial Fibrillation (AF) procedure, the patient had previously undergone an AF ablation procedure, but is still having AF episodes, which can be life threatening and have been shown to lead to strokes. Since the original AF procedure involved burning or freezing of myocardial tissue, this is now additional scar tissue and may cause more complex electrograms and intracardiac signals. In this sub study, both the PURE EP™ system and the GE Cardiolab system will be running and recording signals during the entire procedure, with one of the systems displayed on the screen in the procedure room to guide the physician's decision-making. Even numbered subjects will be PURE EP™ guided and odd numbered subjected will be GE CardioLab guided. All other aspects of the procedure will proceed per standard of care. The study will be collect pulmonary vein signals pre and post ablation therapy, along with other non-pulmonary vein signals of interest during a redo ablation procedure. After the physician has completed ablation treatment, matching signals of interest will be extracted from both the PURE EP™ system and the GE Cardiolab recording system as described in the main study. At a later date, a blinded electrophysiologist reviewer will evaluate the signals from both systems with a focus on tissue viability signals and the impact on the procedure. The survey results will then be compared to see the differences in clinical procedure decision-making based on the signal samples. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04964440
Study type	Observational
Source	BioSig Technologies, Inc.
Contact
Status	Completed
Phase
Start date	March 3, 2021
Completion date	January 29, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05266144` - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting	`NCT06202209` - The Impact of Autonomic Function on Atrial Fibrillation Recurrence After Pulmonary Vein Ablation
Not yet recruiting	`NCT04780438` - Dapagliflozin to Prevent Atrial Fibrillation Recurrence After Transcatheter Pulmonary Venous Isolation.	Early Phase 1
Not yet recruiting	`NCT06098989` - A Prospective Study of REPeat Ablation In Patients With Recurrent PERSistent Atrial Fibrillation: Pulmonary Vein Isolation vs. Adjunct Posterior Wall Isolation (REPAIR PERS-AF Study)	N/A
Recruiting	`NCT05781282` - Pulmonary Vein (PV) Imaging by Intracardiac Echography (ICE) After Ablation	Phase 4
Terminated	`NCT04704050` - Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence	Phase 4
Recruiting	`NCT04968678` - Exploring P-Wave Duration in Arrhythmia Recurrence in Patients Undergoing AF Ablation
Not yet recruiting	`NCT06204640` - SPironolactONe for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation	Phase 3
Recruiting	`NCT06253000` - Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium	N/A
Not yet recruiting	`NCT06199180` - Pulsed Field Ablation Versus Conventional Radiofrequency Catheter Ablation for Repeat PVI in Patients With Paroxysmal AF	N/A
Recruiting	`NCT03075930` - Atrial Fibrillation Ablation Registry
Recruiting	`NCT05528419` - Sacubitril Valsartan in Preventing the Recurrence of Atrial Fibrillation After Ablation in Elderly Hypertensive Patients With Atrial Fibrillation	Phase 4
Not yet recruiting	`NCT06130358` - Investigating the Effects of a Museum Intervention on the Psychological and Cardiac Health of Older Adults	N/A
Completed	`NCT05486364` - DIGITal mOnitoring afTer Af abLation	N/A
Recruiting	`NCT05159180` - Development of a New Impedance Mapping System for Ablation of Atrial Arrhythmias in Patients
Active, not recruiting	`NCT06111443` - Effect of Dapagliflozin on the Recurrence of Atrial Tachyarrhythmia in Patients Undergoing Catheter Ablation of Atrial Fibrillation	Phase 2/Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.